Literature DB >> 22715810

Chromophobe renal cell carcinoma: a review of an uncommon entity.

Francisco Emilio Vera-Badillo1, Esther Conde, Ignacio Duran.   

Abstract

Renal cell carcinoma is the most common neoplasm of the kidney. It is a heterogeneous disease, comprised of different histological variants with a distinct clinical course, genetics and response to treatment. The various subtypes identified include clear cell, papillary and chromophobe, among others. Chromophobe renal cell carcinoma is a rare variant and accounts for 5% of all cases. These tumors are macroscopically larger when compared with other forms and are commonly diagnosed at an early stage. Despite significant advances in renal cell carcinoma therapeutics in the past decade, no standard treatment has been identified for advanced chromophobe renal cell carcinoma. Nevertheless, new molecular insights have recently become available. A familial form of renal cell carcinoma, the Birt-Hogg-Dubé syndrome, has been described and the knowledge obtained has opened research opportunities in the therapeutic arena of chromophobe renal cell carcinoma. The following manuscript will endeavor to provide an overview of this uncommon entity including pathology, epidemiology, genetics, clinical aspects, and current and future treatment options.
© 2012 The Japanese Urological Association.

Entities:  

Mesh:

Year:  2012        PMID: 22715810     DOI: 10.1111/j.1442-2042.2012.03079.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  32 in total

1.  Tremendous non-progressed chromophobe renal cell carcinoma for eight years performed by laparoscope.

Authors:  Yanbo Wang; Xiaobo Ding; Xiaobo Ma; Lingbo Yang; Faping Li; Chunxi Wang; Yuchuan Hou
Journal:  Can Urol Assoc J       Date:  2016-11-10       Impact factor: 1.862

2.  Chromophobe renal cell carcinoma recurrence in the ureter: A late presentation of a rare metastasis.

Authors:  Rebecca Macleod; Pejman Kheirandish; Charles Ondego; Chandra Shekhar Biyani
Journal:  Can Urol Assoc J       Date:  2015-09-09       Impact factor: 1.862

3.  Obesity and renal cell carcinoma risk by histologic subtype: A nested case-control study and meta-analysis.

Authors:  Catherine L Callahan; Jonathan N Hofmann; Douglas A Corley; Wei K Zhao; Brian Shuch; Wong-Ho Chow; Mark P Purdue
Journal:  Cancer Epidemiol       Date:  2018-07-18       Impact factor: 2.984

4.  Bilateral renal cell carcinoma in a paediatric patient with tuberous sclerosis complex.

Authors:  Ana Teresa Gil; Ana Brett; Carolina Cordinhã; Clara Gomes
Journal:  BMJ Case Rep       Date:  2013-07-12

5.  c-Met in chromophobe renal cell carcinoma.

Authors:  Franziska Erlmeier; Philipp Ivanyi; Arndt Hartmann; Michael Autenrieth; Max Wiedemann; Wilko Weichert; Sandra Steffens
Journal:  Med Oncol       Date:  2016-12-29       Impact factor: 3.064

6.  Palliative TACE for hepatic metastases of chromophobe renal cell carcinoma.

Authors:  Peter D Whooley; John Paul Flores; Mehran Fotoohi; Bruce S Lin
Journal:  BMJ Case Rep       Date:  2019-07-15

Review 7.  Prognostic impact of PD-1 and its ligands in renal cell carcinoma.

Authors:  Franziska Erlmeier; Wilko Weichert; Andres Jan Schrader; Michael Autenrieth; Arndt Hartmann; Sandra Steffens; Philipp Ivanyi
Journal:  Med Oncol       Date:  2017-04-21       Impact factor: 3.064

8.  PD-1/PD-L1 expression in chromophobe renal cell carcinoma: An immunological exception?

Authors:  Franziska Erlmeier; Arndt Hartmann; Michael Autenrieth; Max Wiedemann; Philipp Ivanyi; Sandra Steffens; Wilko Weichert
Journal:  Med Oncol       Date:  2016-09-30       Impact factor: 3.064

9.  Genetic alterations of HER genes in chromophobe renal cell carcinoma.

Authors:  Wen Hui Weng; Ying Tzu Chen; Kai Jie Yu; Ying Hsu Chang; Cheng Keng Chuang; See Tong Pang
Journal:  Oncol Lett       Date:  2016-02-08       Impact factor: 2.967

10.  Renal collision tumour of papillary cell carcinoma and chromophobe cell carcinoma with sarcomatoid transformation: A case report and review of the literature.

Authors:  Zhiqiang Zhang; Jie Min; Dexin Yu; Haoqiang Shi; Dongdong Xie
Journal:  Can Urol Assoc J       Date:  2014-07       Impact factor: 1.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.